Updated
The most significant concentration Kestra Medical Technologies, Lt discloses is ASSURE WCD, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Kestra Medical Technologies, Lt’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform, and we are therefore highly dependent on our ASSURE WCD for our continued success.'”
“10-K Item 1A: 'secure second source suppliers if our primary suppliers are unable to fulfill our orders'”
Kestra Medical Technologies' concentration risk centers on product reliance and supplier dependency. The company generates revenue primarily from the lease of its ASSURE wearable cardioverter defibrillator (WCD), a high-share product concentration reflecting how thoroughly Kestra's commercial success depends on a single platform within its Cardiac Recovery System — a mixed exposure, combining a structural feature of a young medical device company built around one core product with the idiosyncratic risk that any regulatory, safety, or competitive setback to the ASSURE WCD specifically would hit the entire business. On the supply side, Kestra discloses a medium-share dependency on its primary suppliers, noting the need to secure second-source suppliers should those primary relationships be unable to fulfill orders — a single-sourcing risk common to specialized device manufacturing. Netting these together, the product concentration is the more consequential exposure: because the ASSURE WCD is effectively the whole business, any disruption there is far more likely to move the investment thesis than a supply interruption, which the company appears to be actively managing by seeking backup sourcing. The supplier risk is real but more conventionally mitigable than the product concentration, which is closer to core business-model risk.
For the engine’s reasoning on KMTS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANGO | AngioDynamics, Inc. | 2 | 0 | 0 | 2 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| KMTS● | Kestra Medical Technologies, Lt | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVR | Anteris Technologies Global Cor | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.